Dr Reddys Laboratories (RDY) Cost of Revenue (2012 - 2026)

Dr Reddys Laboratories' Cost of Revenue history runs 15 years deep, the most recent figure standing at $436.6 million for Q1 2026.

• In Q1 2026, Cost of Revenue changed 0.03% year-over-year to $436.6 million; the TTM figure through Mar 2026 stood at $1.8 billion (up 10.1% YoY), while the FY2026 annual figure was $1.7 billion, up 6.96% from the prior year.
• Cost of Revenue was $436.6 million for Q1 2026 at Dr Reddys Laboratories, down from $454.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $454.4 million in Q4 2025 to a low of $312.0 million in Q2 2022.
• Historically, Cost of Revenue has averaged $371.1 million across 5 years, with a median of $356.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue slipped 13.81% in 2022, then increased 23.51% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $329.0 million in 2022, then rose by 9.31% to $359.6 million in 2023, then advanced by 13.73% to $409.0 million in 2024, then climbed by 11.09% to $454.4 million in 2025, then decreased by 3.91% to $436.6 million in 2026.
• The last three Cost of Revenue figures came in at $436.6 million (Q1 2026), $454.4 million (Q4 2025), and $430.3 million (Q2 2025), per Business Quant data.